Amneal to Acquire Kashiv BioSciences for $750M Upfront, Unveils Strong Q1 Preliminary Results
AMRX sits 83% above its 52-week low of $7.02.
Summary
Amneal Pharmaceuticals announced a definitive agreement to acquire Kashiv BioSciences for $750 million upfront, aiming to become a global biosimilar leader, and reported strong preliminary Q1 2026 financial results.
Key Events · M&A and Partnerships · AMRX
-
Acquisition Agreement
Amneal will acquire Kashiv BioSciences for $750 million upfront ($375M cash, $375M equity), plus up to $350 million in potential milestone payments and royalties.
-
Strategic Expansion
The acquisition is expected to create a global biosimilar leader, adding a robust R&D and manufacturing platform and diversifying Amneal's growth into the 2030s.
-
Equity Dilution
The equity component of the upfront consideration represents approximately 8% dilution, with about 29 million new shares.
-
Strong Q1 Preliminary Results
Reported preliminary Q1 2026 net revenue of $723 million (+4%), adjusted EBITDA of $202 million (+19%), and adjusted EPS of $0.27 (+29%).
Analysis · AMRX · Life Sciences
This DEFA14A filing details Amneal's strategic acquisition of Kashiv BioSciences, a move designed to establish the company as a global leader in biosimilars and extend its growth profile into the 2030s. The upfront consideration of $750 million, comprising $375 million in cash and $375 million in equity (resulting in approximately 8% dilution), represents a significant investment. The company anticipates substantial financial synergies of $400M-$500M over time and expects minimal long-term impact on leverage ratios. Concurrently, Amneal reported robust preliminary Q1 2026 results, with net revenue up 4%, adjusted EBITDA up 19%, and adjusted EPS up 29%, indicating strong operational performance as it embarks on this transformational acquisition. The acquisition is subject to shareholder approval.
At the time of this filing, AMRX was trading at $12.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1B. The 52-week trading range was $7.02 to $15.42. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.